Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Insmed reported a quarterly loss of $1.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.15, and compared to a loss of $1.28 per share a year ago [1] - The earnings surprise for this quarter was -14.78%, and the company has only surpassed consensus EPS estimates once in the last four quarters [2] - Insmed's revenues for the quarter ended December 2024 were $104.44 million, exceeding the Zacks Consensus Estimate by 0.10%, and up from $83.69 million a year ago [3] Stock Performance - Insmed shares have increased approximately 21.4% since the beginning of the year, outperforming the S&P 500's gain of 4.5% [4] - The current Zacks Rank for Insmed is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$1.16 on revenues of $94.72 million, and for the current fiscal year, it is -$4.56 on revenues of $498.2 million [8] - The outlook for the Medical - Biomedical and Genetics industry, where Insmed operates, is currently in the top 27% of over 250 Zacks industries, suggesting a favorable environment for stock performance [9]